Multicenter, Single-Arm, Phase IV Study of Combined Aspirin and High-Dose “IVIG-SN” Therapy for Pediatric Patients with Kawasaki Disease

• Published in: Korean circulation journal Vol. 47; no. 2; pp. 209 - 214
• Main Authors: Yoon, Kyung Lim, Lee, Hae Yong, Yu, Jeong Jin, Lee, Jae Young, Han, Mi Young, Kim, Ki Yong, Huh, June
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Society of Cardiology 01.03.2017; 대한심장학회
• Subjects: Original; 내과학; Immunoglobulins, intravenous; Kawasaki disease; Coronary artery disease; Pediatric
• ISSN: 1738-5520; 1738-5555
• DOI: 10.4070/kcj.2016.0139

Intravenous immunoglobulin-SN (IVIG-SN) is a new human immunoglobulin product. Its safety is ensured by pathogen-elimination steps comprising solvent/detergent treatment and a nanofiltration process. This multicenter clinical study was designed to evaluate the efficacy and safety of combined aspirin and high-dose IVIG-SN therapy in pediatric patients with Kawasaki disease (KD). We evaluated coronary artery lesions (CALs) at 2 and 7 weeks after administering IVIG-SN; total fever duration; and variations in erythrocyte sedimentation rate, N-terminal pro B-type natriuretic peptide or B-type natriuretic peptide, and creatine kinase-myocardial band level before and after treatment with IVIG-SN (2 g/kg). Adverse events were monitored. Forty-five patients were enrolled, three of whom were excluded according to the exclusion criteria; the other 42 completed the study. The male:female ratio was 0.91:1, and the mean age was 29.11±17.23 months. The mean fever duration before IVIG-SN treatment was 6.45±1.30 days. Although most patients had complete KD (40 patients, 90.91%), four had atypical KD (9.09%). After IVIG-SN treatment, one patient (2.38%) had CALs, which was significantly lower than the incidence reported previously (15%) (p=0.022), but not significantly different from recent data (5%). There were no serious adverse events, though 28 patients (63.64%) had mild adverse events. Three adverse drug reactions occurred in 2 patients (eczema, anemia, and increased eosinophil count), all of which were transient. IVIG-SN treatment in patients with KD was safe and effective.